Tonix Pharmaceuticals (NASDAQ:TNXP) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Performance

TNXP opened at $0.33 on Wednesday. The company has a market capitalization of $61.64 million, a price-to-earnings ratio of -0.01 and a beta of 2.23. The business’s 50-day moving average price is $0.23 and its two-hundred day moving average price is $0.37. Tonix Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $14.08. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Equities analysts expect that Tonix Pharmaceuticals will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.